Literature DB >> 19399291

InterStim Therapy: A Contemporary Approach to Overactive Bladder.

Neeraj Kohli1, Danielle Patterson.   

Abstract

Overactive bladder is a common and challenging condition for the practicing obstetrician-gynecologist. The prevalence of the condition is increasing with our aging population. Although some patients respond to first-line therapy, a significant number will require sacral nerve stimulation to address the underlying neurologic condition that causes overactive bladder as well as other pelvic floor conditions. This article summarizes the epidemiology and symptomatology, office evaluation, and treatment of overactive bladder with particular emphasis on sacral nerve stimulation (SNS). SNS technique, results, and future applications are also reviewed.

Entities:  

Keywords:  InterStim Therapy; Neuromodulation; Overactive bladder; Sacral nerve stimulation

Year:  2009        PMID: 19399291      PMCID: PMC2672997     

Source DB:  PubMed          Journal:  Rev Obstet Gynecol        ISSN: 1941-2797


  15 in total

1.  Sacral neuromodulation for the treatment of refractory urinary urge incontinence after stress incontinence surgery.

Authors:  Neil D Sherman; Margaret G Jamison; George D Webster; Cindy L Amundsen
Journal:  Am J Obstet Gynecol       Date:  2005-12       Impact factor: 8.661

2.  Impact of overactive bladder on women in the United States: results of a national survey.

Authors:  Roger R Dmochowski; Diane K Newman
Journal:  Curr Med Res Opin       Date:  2007-01       Impact factor: 2.580

3.  Validation of an overactive bladder awareness tool for use in primary care settings.

Authors:  Karin S Coyne; Teresa Zyczynski; Mary Kay Margolis; Victor Elinoff; Richard G Roberts
Journal:  Adv Ther       Date:  2005 Jul-Aug       Impact factor: 3.845

4.  Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study.

Authors:  Philip E V van Kerrebroeck; Anco C van Voskuilen; John P F A Heesakkers; August A B Lycklama á Nijholt; Steven Siegel; U Jonas; Clare J Fowler; Magnus Fall; Jerzy B Gajewski; Magdy M Hassouna; Francesco Cappellano; Mostafa M Elhilali; Douglas F Milam; Anurag K Das; H E Dijkema; Ubi van den Hombergh
Journal:  J Urol       Date:  2007-09-17       Impact factor: 7.450

5.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

6.  The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence.

Authors:  Jeanette S Brown; Catherine S Bradley; Leslee L Subak; Holly E Richter; Stephen R Kraus; Linda Brubaker; Feng Lin; Eric Vittinghoff; Deborah Grady
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

7.  Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?

Authors:  Cindy L Amundsen; Audrey A Romero; Margaret G Jamison; George D Webster
Journal:  Urology       Date:  2005-10       Impact factor: 2.649

8.  Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms.

Authors:  Manish Gopal; Kevin Haynes; Scarlett L Bellamy; Lily A Arya
Journal:  Obstet Gynecol       Date:  2008-12       Impact factor: 7.661

9.  Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Authors:  Michael B Chancellor; Norman Zinner; Kristene Whitmore; Kathleen Kobashi; Jeffrey A Snyder; Paul Siami; Mickey Karram; Christine Laramée; James P Capo'; Raafat Seifeldin; Sergio Forero-Schwanhaeuser; Indrani Nandy
Journal:  Clin Ther       Date:  2008-10       Impact factor: 3.393

Review 10.  Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review.

Authors:  Miriam Brazzelli; Alison Murray; Cynthia Fraser
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

View more
  7 in total

1.  Real-time, autonomous bladder event classification and closed-loop control from single-channel pressure data.

Authors:  Robert Karam; Swarup Bhunia; Steve Majerus; Steven W Brose; Margot S Damaser; Dennis Bourbeau
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2016-08

2.  Gastric Electrical Stimulation and Sacral Electrical Stimulation: A Long-Term Follow-Up Study of Dual-Device Treatment.

Authors:  Anubhav Agrawal; Sean Lamar Francis; Nicolette Elizabeth Deveneau; Shaily Jain; Christopher Abrasley; Jason Trippe McNeese; Shivangi T Kothari; Christopher J Lahr; Thomas L Abell
Journal:  Dig Dis Sci       Date:  2015-08-18       Impact factor: 3.199

3.  Cholinergic Antagonists Combined with Electrical Stimulation or Bladder Training Treatments for Overactive Bladder in Female Adults: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Yang Cao; Jianwei Lv; Chen Zhao; Jiayi Li; Jing Leng
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

4.  Pelvic electrical neuromodulation for the treatment of overactive bladder symptoms.

Authors:  Tariq F Al-Shaiji; Mai Banakhar; Magdy M Hassouna
Journal:  Adv Urol       Date:  2011-05-14

Review 5.  Sacral neuromodulation in overactive bladder: a review and current perspectives.

Authors:  Troy Sukhu; Michael J Kennelly; Raj Kurpad
Journal:  Res Rep Urol       Date:  2016-10-26

6.  Neuromodulation for functional bladder disorders in patients with multiple sclerosis.

Authors:  Mohammad Sajjad Rahnama'i
Journal:  Mult Scler       Date:  2019-12-09       Impact factor: 6.312

7.  Selectivity of afferent microstimulation at the DRG using epineural and penetrating electrode arrays.

Authors:  Ameya C Nanivadekar; Christopher A Ayers; Robert A Gaunt; Douglas J Weber; Lee E Fisher
Journal:  J Neural Eng       Date:  2019-12-13       Impact factor: 5.043

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.